Home
Resources
Publications
Drug Hepatotoxicity: Newer Agents

Drug Hepatotoxicity: Newer Agents

Chalermrat Bunchorntavakul, K Rajender Reddy

Clin Liver Dis. 2017 Feb;21(1):115-134.

PMID: 27842767

Abstract:

Idiosyncratic hepatotoxicity is one of the most common reasons for an approved drug being restricted. This article focuses on hepatotoxicity of selected and recently introduced agents, such as, tyrosine kinase inhibitors, monoclonal antibodies, novel oral anticoagulants, newer antiplatelets, antibiotics, anti-diabetics, anti-epileptics, anti-depressants, anti-psychotics and anti-retrovirals. Overall, the incidence of clinically relevant hepatotoxicity from newer agents seems to be lower than that of the older agents. Nevertheless, cases of severe hepatotoxicity have been reported due to some of these newer agents, including, trastuzumab, ipilimumab, infliximab, imatinib, bosutinib, dasatinib, gefitinib, erlotinib, sunitinib, ponatinib, lapatinib, vemurafenib, dabigatran, rivaroxaban, felbamate, lamotrigine, levetiracetam, venlafaxine, duloxetine, darunavir, and maraviroc.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP25451154-B	Felbamate		25451-15-4	Price
AP380843754	Bosutinib		380843-75-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: